A randomized, placebo-controlled phase II clinical trial of combination erlotinib (Tarceva) and celecoxib (Celebrex) versus erlotinib (Tarceva)/placebo in advanced non-small cell lung cancer patients.

Trial Profile

A randomized, placebo-controlled phase II clinical trial of combination erlotinib (Tarceva) and celecoxib (Celebrex) versus erlotinib (Tarceva)/placebo in advanced non-small cell lung cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Celecoxib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 10 Feb 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top